Clinical trials in surgery suggest that some failures of antibiotic prophylaxis are related to the in vivo degradation of b-lactams by Staphylococcus aureus b-lactamase. To explore this issue further, isogeneic isolates of S. aureus differing only in whether they contained the structural gene for type A staphylococcal b-lactamase were constructed and compared for their ability to establish an abscess in a guinea pig model. With ampicillin prophylaxis, the ID 50 was 870 cfu for the b-lactamasenegative isolate VK7114 and 240 cfu for the b-lactamase -producing isolate VK7115 (P õ .001). Similarly, the ID 50 was greater for the b-lactamase -negative isolate when cefazolin prophylaxis was administered (599 vs. 128 cfu, VK7114 and VK7115; P õ .001). In the setting of prophylaxis with b-lactamase -susceptible antibiotics, b-lactamase contributes to the pathogenesis of S. aureus wound infections.
An estimated 325,000 -920,000 postsurgical wound infecIt is unclear why the production of b-lactamase should contribute to the development of an S. aureus wound infection. tions occur annually in the United States [1 -3] . Staphylococcus aureus is the prototypic clean wound pathogen and causes more Whereas S. aureus is primarily a pathogen in clean surgical procedures, in which the bacterial inoculum is believed to be postsurgical infections than any other organism [4] . Under conditions of an accompanying foreign body or in the presence of very low, the in vitro demonstration of b-lactam resistance by methicillin-susceptible b-lactamase -producing isolates of S. devitalized tissue, it can establish a wound infection with an extremely small inoculum, possibly as low as 1 cfu [5 -9] .
aureus has required a large bacterial inoculum [12 -18] . In this study, we evaluated isogeneic S. aureus isolates that differ only Although concepts of the pathogenesis of infection are commonly described in terms of the interactions between microbial in whether they produce b-lactamase in a low-inoculum in vivo model of staphylococcal abscess formation to test the virulence factors and host defenses, this model is probably inadequate for understanding the pathogenesis of surgical hypothesis that staphylococcal b-lactamase contributes to the pathogenesis of wound infection and reduces the efficacy of wound infections. As prophylactic antibiotics are administered routinely with many surgical procedures to reduce the risk of antibiotic prophylaxis. infection, the interactions between microbial resistance factors and antibiotics may be just as important as those between Materials and Methods microbial virulence factors and host defenses in determining whether a wound infection complicates the operation. Clinical Construction of isogeneic S. aureus isolates. Isolate DK2076 trials and animal models have shown that antibiotics do not is a clinical isolate recovered during surveillance cultures of the prevent wound infection by antibiotic-resistant pathogens nares of operating room personnel at Saint Thomas Hospital in [7 -10] . Partial antibiotic resistance, such as that exhibited by Nashville in 1986. It is a phage group 94/96 isolate, yet is remarksome b-lactamase -producing isolates of S. aureus to a relaable in that it does not possess plasmids or produce b-lactamase, tively b-lactamase -labile antibiotic such as cefazolin, has also in contrast to the majority of phage group 94/96 isolates, which been implicated as a cause of some failures of antibiotic procontain a 17.2-kb plasmid, produce large amounts of type A staphphylaxis [11] .
ylococcal b-lactamase, and exhibit borderline susceptibility to the antistaphylococcal penicillins [19] [20] [21] . An E. coli-S. aureus shuttle vector, pVK101, was constructed with erythromycin as a selectable marker in S. aureus. First, the S. aureus plasmid pE194 was digested with SalI and cloned into to create pVK102. In this clone, the 3 end of the blaZ-containing was mixed in a 1/1 (vol/vol) ratio with sterile dextran microbeads (Cytodex; Sigma, St. Louis). Backcounts were done in triplicate insert is close to a HindIII site in the polylinker region of pTZ18R vector. Subsequently, HindIII digestion of pVK102 enabled the and averaged to determine the precise bacterial inoculum. On the day of in vivo experimentation, the dorsal hair was type A blaZ to be mobilized on a 1.1-kb fragment, which was cloned into pVK101 to produce pVK103 (figure 1).
removed from albino Hartley guinea pigs of either sex, weighing 500 { 50 g (Harlan Sprague-Dawley, Indianapolis), and a grid was S. aureus isolate VK7114 was produced by introducing pVK101 into DK2076 by using protoplast transformation with RN4220 drawn designating 12 areas for intermuscular inoculation. Each site was inoculated with 0.2 mL of one of the bacteria-bead suspen-(from RP Novick, Public Health Research Institute, New York) as an intermediate host [24] . S. aureus isolate VK7115 was produced sions. For animals receiving ampicillin or cefazolin prophylaxis, 100 mg/kg was administered subcutaneously at the time of bacteby protoplast transformation of pVK103 into DK2076.
In vitro characterization of S. aureus isolates. Determinations rial inoculation. Control (placebo) guinea pigs received prophylaxis with saline at the time of bacterial inoculation. After the of b-lactamase type and quantity were done using whole-cell suspensions of bacteria and previously described methods [11, 25] .
administration of antibiotic prophylaxis and inoculation with the bacteria-bead suspensions, the guinea pigs were returned to their Methicillin at a subinhibitory concentration of 0.5 mg/mL was used to induce b-lactamase production. Microdilution broth MICs were cages. Two poorly absorbable antibiotics, gentamicin (80 mg/mL) and polymyxin B (50 mg/mL), were added to their drinking water determined by use of standard techniques [26] , except that the inoculum size was varied over a range from 10 1 to 10 8 cfu/mL. to reduce the risk of mortality from prophylactic antibiotic-associated colitis [6, 27] . Assays were done in 2% salt-supplemented Mueller-Hinton broth (Difco, Detroit), and results were determined after 24 h of incubaAfter 3-4 days of confinement, the guinea pigs were sacrificed and new growth dorsal hair was removed by depilation. By sterile tion at 35ЊC.
In vivo procedures. Details of this low-inoculum prophylaxis technique, microbeads, with or without adherent abscess material, were removed from each of the 12 sites and inoculated onto sheep model have been described previously [6] [7] [8] [9] . S. aureus colonies were harvested after overnight growth on tryptic soy agar and blood agar plates. The plates were incubated at 35ЊC for 24 h, and the presence or absence of bacterial growth was recorded. suspended in PBS to achieve a standard turbidity. Serial 10-fold and 2-fold dilutions were done to prepare a range of inocula that Data analysis and statistical determinations. Logistic regression was used to assess the effect of different prophylactic regiproduced an abscess from 0 to 100% of the time. Each dilution mg/kg cefazolin was administered (P õ .001).
Results

Discussion
Construction and in vitro characterization of isogeneic S. aureus isolates. Isogeneic isolates of S. aureus that differ
We have shown that the inoculum of bacteria required to establish a soft tissue infection in the setting of prophylaxis only in whether they produce type A staphylococcal b-lactamase were constructed by transforming the E. coli -S. aureus with ampicillin or cefazolin is smaller for a b-lactamase -producing isolate of S. aureus than for its paired isogeneic isolate shuttle vectors pVK101 and pVK103 into the plasmid-free, b-lactamase -negative S. aureus isolate DK2076 to produce lacking b-lactamase activity. This observation supports the hypothesis that the in vivo hydrolysis of a relatively b-lactamaseisolates VK7114 and VK7115, respectively. As pVK101 and pVK103 (figure 1) are identical except for the presence of the labile antibiotic by b-lactamase enables an S. aureus isolate to survive prophylaxis and contributes to the pathogenesis of type A b-lactamase structural gene, blaZ, in pVK103, VK7114 and VK7115 were identical except that only VK7115 produced a clean surgical wound infection [11] . Furthermore, S. aureus resistance is demonstrable in vivo with inocula in the 10 2 -to b-lactamase. When induced with subinhibitory concentrations of methicillin, VK7115 hydrolyzed ampicillin and cefazolin 10 3 -cfu/mL range, whereas the in vitro demonstration of a twotube, 4-fold difference in the MIC of VK7114 and VK7115 at rates of 225 and 1.5 mg/min/10 8 cfu, respectively. This is comparable to hydrolysis rates exhibited by most phage group required inocula of §10 5 cfu/mL (table 1) . Why S. aureus resistance to b-lactams that can be reliably 94/96 isolates, which generally produce large amounts of type A b-lactamase and exhibit borderline susceptibility to the antiidentified only with large inocula in vitro can be demonstrated with small inocula in vivo might be related to differences in staphylococcal penicillins [19 -21] . During in vitro susceptibility testing, only VK7115 demonstrated a marked inoculum the diffusion capabilities of antibiotics under these conditions. In vitro susceptibility testing is done in media that allow rapid effect with ampicillin and cefazolin (table 1) .
In vivo prophylaxis studies. To test directly the contribudiffusion of antibiotics, with the result that new molecules of b-lactam can replace those that the bacteria degrade. As gramtion of b-lactamase production to failures of prophylaxis in a low-inoculum guinea pig model, we determined the ability of positive bacteria lack an outer cell membrane, single bacteria [30, 31] prompted the recommendation that more stable b-lactams should be used [32] . Similarly, the introduction of cefazolin into clinical practice in the mid-1970s was followed by reports of its susceptibility to b-lactamasemediated degradation [12 -18] . Sporadic reports of clinical treatment failure with cefazolin in endocarditis raised questions about whether cefazolin-hydrolyzing b-lactamases adversely influenced the outcome of therapy [33, 34] . Others interpreted these few reports of therapeutic failure as reflecting the inherent difficulties in managing endocarditis and cautioned against rejecting the use of cefazolin in staphylococcal infections on the basis of uncontrolled studies [35] .
Using in vivo models, several investigators have addressed the role of b-lactamase -mediated hydrolysis of cefazolin in treatment failure. Chapman and Steigbigel [36] found that S. aureus isolates that exhibit relative resistance to cefazolin (using high-inoculum MICs) responded less favorably to therapy with cefazolin than did other, more b-lactamase -stable antibiotics in a murine model of peritonitis. Furthermore, S. aureus isolates that lacked an inoculum effect to cefazolin were effectively treated with cefazolin in vivo. Conclusions derived from animal models of endocarditis have been mixed, with some studies supporting [37, 38] and others disputing [39, 40] the importance of b-lactamase -mediated cefazolin hydrolysis in influencing the response to therapy. Fields et al. [41] concluded that cefazolin was inactivated in vivo by an isolate of S. aureus producing type A b-lactamase on the basis of their recovery of less bioactive cefazolin than cefmetazole from tissue cages in rabbits that had been infected with this isolate, despite favorable serum pharmacokinetics of cefazolin and no differences in the concentrations of the two drugs in uninfected tissue cages. In each of these studies, the activity of cefazolin was compared with that of a more b-lactamase -stable drug.
Because of differences in the pharmacokinetics of different 
